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Efficacy, side effects and predictors of response for intra-
venous amfodarone were evaluated in 46 patients with
recurrent drug-refractory sustained ventricular tachyear-
dia or ventricular fibrillation, or both, who were treated
with intrnveumandndarane.Of lhe46 patients, 27 (55.5%)
responded early to Intravenous amiodarone and 6 (13%)
showed a !me response to andudarwre. The majority or
patients who responded to intravenous amdodaroe did so
within the first 2 h of therapy, and all responded within 84 Is .
Patients with an ejection fraction >25% were more likely to
respond (p < 0 .05) . Major side effects occurred in 13% of
patients. The cumulative 2 year mortality rate due to
arrhythmiv recurrence or sudden death for responders
Amoodarone, administered orally, is effective in patients
with recurrent ventricular tachycardia and ventricular fibril-
lation
(I).
However, long-term oral dosing requires 8 days to
4 weeks to reach maximal effect (2-4) . Because amiodarone
has unique pharmacokinetic properties (5) and its primary
mode of antiarrhythmic action is uncertain, the possibility
that its slow onset of activity can be shortened by treating
patients with the intravenous form of amiodarone has
seemed doubtful. We previously reported (6) our preliminary
experience with intravenous amiodarone and found it to be
effective in some patients with malignant ventricular
arrhythmias refractory to other agents . However, the treat-
ment protocol in that group of patients was variable and the
size of the group was small
. On the basis of that experience
and a follow-up study of the hemodynamic response to
intravenous amiadarone (7), we developed a more uniform
treatment protocol.
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discharged from the hospital was 23% and the cumulative
overall 2 year mortality rate was 46% .
In conclusion, intravenous amiodarmne h rapidly effec
live in the majority of patients with recurrent ventricular
tarhycardia or ventricular fibrillation refectory to other
drugs. The poorlang-term outcome of patieals who require,
this therapy, respond to it and are discharged on long-term
oral amiodarone therapy warrants consideration of other
long-term treatment of these pa0^nts. Use of intmenous
amiodarone is a important new modality in the treatment
of drug-refractory mahptont
ventricular
arrhythmias .
(J An, Call Cordial 1488
;12
:1015-22)
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In this report, we present our experience using this
treatment protocol in a larger group of patients who had
ventricular tachycardia or ventricular fibrillation refractory
to at least two other antiarrhythmic agents . This report
corroborates our earlier fading-, (6) as well as reports by
others (8-11) of the efficacy of intravenous amiodarone in
smaller groups of patients with drug-refractory ventricular
tachycardia and ventricular fibrillation . It extends our pre-
vious findings in describing not only the incidence of re-
sponse, but also the time course of response, the clinical
characteristics that predict a successful response, the hospi-
tal course of responders and nonresponders, major side
effects and long-term follow-up of patients treated with
intravenous amiodarone .
Methods
Inclusion and exclusion criteria . Inclusion criteria: Pa-
tients with life-threatening recurrent sustained ventricular
tachycardia or ventricular fibrillation that did net rev-,00 to
at least two other antiarrhythmic medications . Patients were
admitted to the study regardless of the severity of cardiac
dysfunction .
035-1997f88R3.50
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Exclusion criteria : I) Patients who had received oral
amiodarone for >2 days before initiation of the intravenous
drug (four patients) ; 2) patients who had had a myocardial
infarction <2 days before initiation of intravenous amioda-
rone (one patient) ; 3) patients who had taken an antiarrhyth-
mic drug that appeared to have exerted
a proarrhythmic
effect (onset of new or incessant ventriculartachycardta)
and
that was stopped at the start of the amiodarone infusion (five
patients) .
Of 56 consecutive patients eligible for inclusion, 10 were
excluded for the reasons indicated . The remaining 46 pa-
tients are the subject of this report . Patients previously
reported from this institution by Morady et al. (6) and
Schwartz et al . (7) are not included in this report .
Definitions. Sustained ventricular tachycardia
:
ventricu-
lar tachycardia lasting >30 s or requiring intervention for
termination.
Incessant ventricular tachycardia : continuous or recur-
rent episodes of sustained ventricular tachycardia or ventric-
ular fibrillation more frequent than one episode every 2 h
over a 12 h period .
Response to intravenous amiodarone : resolution of epi-
sodes of sustained ventricular tachycardia during the lime of
the infusion and absence of other episodes for 48 h after its
discontinuation.
Late response to amiodaone : resolution of episodes of
sustained ventricular tachycardia after discontinuation of the
infusion and during treatment with oral amiodarone .
Time to response : time of the last episode of sustained
ventricular tachycardia as measured from the start of ther-
apy with intravenous amiodarone . This time was taken to be
0 h in patients who had no episodes of sustained ventricular
tachycardia after an initial bolus injection.
Major side effects: those that required either therapeutic
intervention or discontinuation of the infusion .
Analysis of data
. Corrected QT intervals (QTc) : QT inter-
vals were measured in patients in whom an
electrocardio-
gram (ECG) could be obtained at the start of the infusion and
after 3 days of the infusion while they were taking
no other
antiarrhythmic drug (this was possible in 17 patients) . The
QTc interval was calculated by correction of the
QT interval
to heart rate (RR) using Bazett's formula : QTc = QT/V.
Long-term follow-up: long-term follow-up was provided
by referring physicians or through patient visits to the
arrhythmit clinic.
Statists,s: differences between responders and nonre-
sponders with respect to pretreatment clinical characteris-
tics, in-hospital mortality and QTc prolongation were as-
sessed with the use of chi-square or Student's t lest.
Fischer s exact test was used instead of the chi-square test if
a group was predicted to contain fewer than
five subjects.
Patient survival and the incidence of arrhythmia recurrence
or sudden death was evaluated by life table analysis (12).
LACE V.1 12, Nn, d
0aS,19
,
NN :1015-22
Treatment protocol. The treatment protocol was deter-
mined prospectively, but changes were allowed at the dis-
cretion of the attending physician . Amiodarone was admin-
istered through a central venous line in a loading dose of 5
mg/kg body weight infused over 30 min followed by a
continuous infusion of I g/24 h for 72 h . The infusion was
discontinued sooner than 72 h in two patients
who demon-
strated a proarrhythmic effect and in five patients who
responded promptly to the infusion
. The infusion was con-
tinued for >72 h in six patients who did not respond to
intravenous amiodarone by 72 h and in three patients who
did respond by 72 h but who could not take oral amiodarone
at the end of 72 h. Additional bolus injections of intravenous
amiodarone (100 mg) were occasionally given to patients if
their arrhythmia recurred during the infusion .
All patients who responded to intravenous amiodarone
and
all
patients who did not respond and did not experience
a proarrhythmic effect of intravenous amiodarone were
treated with oral amiodarone, 800 mg/day, after the end of
the infusion
. Other therapies were used in nonresponders
when appropriate . These included other antiarrhythmic
drugs, overdrive pacing, catheter ablation and endocardial
resection. Patients received continuous ECG monitoring
during the infusion of amiodarone (in the coronary care unit)
and for at least the first 5 days after the last recurrence of
ventricular tachycardia during oral amiodarone therapy.
Rhythm strips were obtained of all episodes of sustained
ventricular tachycardia or fibrillation and usually of episodes
of unsustained arrhythmia .
Results
Patient and arrhythmia charactcrlstics. The 46 patients
included had not responded to 3 .2 ± 0.4 (mean ± SD)
antiarrhythmic agents . Before being treated with intrave-
nous amiodarone, their most recent episode of ventricular
tachycardia had lasted from 2 .5 h to 3 weeks (Table I) .
Forty-five of the 46 patients required cardioversion at some
time during their hospital course before amiodarone therapy
to terminate episodes of ventricular tachycardia or fibrilla-
tion, and 20 patients required overdrive ventricular pacing .
For the group as a whole, 3 .0 ± 0.4 direct current cardio-
versions had been required for resuscitation during the 24 h
period before treatment with intravenous amiodarone . Six-
teen patients had incessant ventricular tachycardia or
Ven-
tricularfibrillation in the 24 h before the start of the infusion.
Ten patients had been unsuccessfully treated with intrave-
nous bretylium tosylate before the start of the infusion .
Incidence
and
time course of response. Twenty-seven
(58.5%) of the 46 patients responded to intravenous amioda-
rone, and an additional 6 patients (13%) showed a late
response to amiodarone (Fig. I„ Fifteen of the 27 responders
(33% of all patients) responded immediately (0 to 2 h), and 26
responded within 72 h . The other patient responded within
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'Denotes innesant ventricular Iachycaolia (VT) in 24 h before infusion; No
. of episodes = number of episodes
ofsostained ventricular tachycardia or ventricular fibrillation during the time marked duration : C = continuous; CHF
= congestive heart failure ; Duration - duration of ho,r italivrtiun before ,ran of infusion: EF= ejection fraction
; FU
= follow-up; I = ineassanC NC = noncardiac
: NR = non-ponder:S13 = sudden death .
84 h (Fig. 2) . The patients who eventually responded to oral There were 16 patients with incessant ventricular tachy-
amiodarone experienced their last episode of sustained ven-
cardia during the 24 h before the start of infusion. The
tricolor tachycardia on the 5th to 12th day after the start
of incidence and time course of response in these patients were
the infusion.
similar to those of the group as a whole
: 9 (56%) responded
Patient
No
. EF111
Duraion
Idaysl
No. of
Eplsodac
Time
Res nse
Ihl
Follow -up
Du
ra
tion
Outcome
I' 50 0.1 C 0 2 yr Died .NC
2' 29 0.5 1 11 In hospital Dnd .VT
3 19 I t 0 No FU No FU
4 45 3 0 1 .8 yr Alive
5 15 3 11 1 .3 yr Alive
fi 30 5 3 0 3 yr Alive
7 20 5 4 0 In hosptal Died,VT
8 15 7 In hospital Died,NC
9 40 8 3
0 2
.6
yr Alive
10 30 II
6
0
Dind
.VT
11 30 12 2 0
11 1
.3 yr Died
.VT
12' 45 I C 1 .6 yr Alive
13 37 0,2 5 2 .5 yr Alive
14' 65 0 .66 C 11 ye Died,SD
15' 40 21 40 1.8 yr Alive
16' 34 I 8 to .. Died,SD
17' 14 9 I 12 3 no Died .NC
18 35 1 3 16 3.6 yr
Alive
19
17
14 I0
I6
3 m0
DIed,CHF
20
32
5
2 22
2
.5 yr
D6d.SD
210 42 7 I
48 2
.9 yr
Ahvc
22
IS
10
4 48 I yr Alive
23 70 7 10 60 3 .5 ye Alive
24 36 7 0 64 3 .7 yr Alive
25 35
5 3 72
3 m0
Died .VT
26 I! to 72 1 .9 yr INnd .CHF
27' 35 C 84 In hospital Died,CHF
28'
46
1 120 4 yr Alive
29' 45 4
1 120 2 .5 yr Alive
300 15 5
C 144 1.5 ye Ded,CHF
31 45 6 4
168 I yr Alive
32 30
5 192
2 In. Died.CHF
33 33 I5
240 No FU No FU
34 23 I NR In hospital
Died.VT
35 20 - 3 NR
In hospital DIed,VT
36 48 2 to NR In hospital Died,VT
37
16
2 4 NR In hospital Died .VT
38 40 3 IS NR Inhosptal Died,CHF
39 23 7 2 NR 3.3 yr Alive
40 40 8 8 NR 3me Died,SD
41 17 8 7 NR In hospital Died,VT
42' 23 8 I NR In hospital Died .CHF
45 35 9 25 NR I yr Alive
440
15
9
20 NR In hospital Died,VT
45 19
14 4 NR In hospital DIed.YT
46' 28 21 1 NR 12'yr Alive
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F re 1. Hospital course of 46 patients (pts). IVA = intravenous
amiodarone; nonresp = nonresponders ; oral A
x
oral amiodarone ;
recur = recurrences; p-
response .
to intravenous amiodarone and 3 (19%) ultimately responded
to oral amiodarone (late response) ; 5 (31%) responded im-
mediately (0 to 2 h) and IS of 16 responded within 72 h ; the
16th patient responding within 84 h . Of the 10 patients who
had not responded to intravenous bretylium, 6 responded to
intravenous amiodarone, 2 were late responders to amioda-
rone and 2 were nonresponders.
Predictors of in-hospital response. Of the pretreatment
clinical characteristics evaluated to predict a response to
intravenous amiodarone or to the combination of intrave-
nous plus oral amiodarone, only an ejection fraction >25%
predicted a positive response (Table 2) .
Hospital coarse and regimen at discharge. In the 33 re-
sponders, other antiarrhythmic drugs that had previously
failed to control the arrhythmia were used during the infu-
sion in 15 patients. Six of these 15 patients were eveatually
discharged on another antiarrhythmic agent in addition to
amiodarone. Other antiarrhythmic drugs were used at some
time during the infusion in all nonresponders .
Responders and nonresponders showed marked differ-
ences in overall hospital mortality (4 of 33 versus 9 of 13,
respectively, p < 0.001) and in deaths due to arrhythmia
(arrhythmic mortality) (2 of 33 versus 7 of 13, respectively, p
< 0 .001) . Arrhythmic deaths in nonresponders occurred on
days 4 to 8 in five patients and on days 10 and 15 in the other
two patients .
JA CC V.I . 12. No. 4
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Figure 2 . Time course of response in 46 patients . Response during
the first 3.5 days occurred during intravenous infusion of amioda-
rone ; response afer3.5 days occurred during oral administration of
amiodarone.
Nonpharmacologic therapy was used whenever appropri-
ate in nonresponders. Of the seven patients in whom non
.
pharmacologic therapy could be used (surgery five, catheter
ablation one, overdrive ventricular pacing one, three (43%)
died, whereas all six patients for whom such therapy could
not be used died (p < 0.05).
Of the 27 responders to intravenous amiodarone, 6 had
recurrent ventricular tachycardia on days 6 to 8.
Of these,
two died of recurrent ventricular tachycardia, one required
the addition of another antiarrhythmic agent to oral amioda-
rone before discharge and three were eventually discharged
receiving oral amiodarone as the only antiarrhythmic agent .
Major side effects. Side effects requiring other interven-
tions or discontinuation of the infusion occurred in six
patients (13%). Hypotension requiring active treatment oc
.
curred in two patients . One patient, who had an ejection
fraction of 42%, developed hypotension I h after receiving a
loading dose of intravenous amiodarone along with infusions
of bretylium and lidocaine hydrochloride ; dopamine was
required for I h . The other patient developed hypotension 3
h after the start of the infusion. This patient had an ejection
fraction of 20% and had significant congestive heart failure
before the infusion . Treatment with dopamine was started
and blood pressure normalized immediately; he was treated
with dopamine and nitroprusside for 2 days . Intravenous
amiodarone was continued for a total of 3 days without other
episodes of hypotension. Of the other 46 patients, 6 were
being treated with pressor agents at the start of the infusion
and continued to receive these agents during part or all of the
time of the infusion. Therefore, hypotension caused by
intravenous amiodarone could not be assessed in these
patients. All six of these patients had a past history of
congestive heart failure and three had an ejection fraction
<25%. However, 13 other patients with a history of conges-
tive heart failure and 13 patients with an ejection fraction
<25% who were included in this study did not experience
hypotension during the infusion .
Two patients required pacing for sinus bradycardia. In
JACC Vol . 12. No.4
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CAI) =coronary artery disease : EF = ejection
ratchet
: MI = myocardial infarction : NS - our significant: VT
= ventricular tachycardia: other abbreviations as in Table l .
one patient, symptomatic bradycardia occurred I h after the
infusion was started and temporary pacing was required for
8 h. The other patient had been treated with intravenous
amiodarone for 48 h and oral amiodarone for 3 days when he
developed symptomatic sinus bradycardia with an escape
functional rhythm at 40 beatsimin . This was the only patient
who required permanent pacing as a result of amiodarone
therapy.
Two patients with episodes of recurrent mouoeoorphic
ventricular tachycardia developed polyotorpltous ventricular
tachycardia after intravenous arniodaroere . The QTc interval
for these patients lengthened from 400 and 390 ms before
administration
of
amiodarone to 510 and 650 ms, respec-
tively,
after 2 days of intravenous and I day of oral amioda-
rone . Oral amiodarone was continued in one of the patients
for an additional 5 days when it had to be discontinued
because of development of polymorphous ventricular tachy-
cardia. The patient was managed with phenytoin and over-
drive ventricular pacing and was eventually discharged on
this regimen . Amiodarone was discontinued
immediately in
the second patient but this patient died of refractory poly-
morphous ventricular tachycardia and fibrillation on the 4th
day of therapy .
Corrected QT interval (Table 3). After 3 days of amioda-
rune treatment the QTc interval was prolonged by 720 ms in
12 of the 17 patients studied . There was no difference in
either absolute or percent QTc prolongation between re-
sponders and nonresponders, excluding the two patients
who experienced arrhythmia exacerbation
. The latter two
patients had the greatest QTc prolongation, 120 and 260 ms,
respectively, compared with a maximum of 100 ms for the
other 15 patients . Similar results were found in evaluation of
the uncorrected QT intervals .
Long-term follow-up . Of the 29 responders who were
discharged from the hospital, follow-up was available for 27 .
For these 27 patients, the cumulative mortality at I year of
follow-up was 23 ± 8% (mean'_ SEM by life table analysis)
and at 2 years was 46'_ 11%. The cumulative mortality due
to arrhythmia recurrence or sudden death at I year was 13 ±
4% and at 2 years was 23 2 7% . The overall
arrhythmia
recurrence rate at 2 years was 25 ± 9%. Of the 12 deaths that
occurred during follow-up, 6 were arrhythmic or sudden . 4
Table 3
. Corrected Qt Qt,) Measurements Before and 3 Days After Start of Amiedarone
Treatment in 17 Patients
HELMY ET AL .
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(400.390) (520.650) (120
.260)
'P < 0.05 . IVA = intravenous admiodarune
; e = number of patients; Pis = patents ; Qt,(O) = corrected Qt,
interval before start of infusion : Q1,13d) = QI, aaer 3 days of amiodamne treatment . WI, = Ql,(O) - Qsdtd) .
Table 2. Pretreatment Clinical Characteristics of Responders and Nonreseondees
Responders
In
=331
Nonrcspondern
In =13) V.I..
NSMean age (range) (55) 64 (191o S4) 633145,e, 94)
No . of drugs failed 3
.35
3 .15 NS
Patients with incessant V'1 12 4 NS
Patients with Ml 2 to 7 days before 4 I NS
infusion
Patients with CHF
It NS
Patients with diagnosis of CAI)
2?
12
NS
Patients with nonisehemic cardiomyopathy 4 I NS
Patients with aortic stenanis 1 0 NS
Mean EF tar groop 91) 3 26 .7 NS
Patients with EF >25%r 5 0.04
Patients with arrhythmia duration cI day I
NS
Mean Qt, (0)
Interval
(. .get (ms)
Mean
QI,
(3d) Interval
(rennet (ms)
Mean
.1Qt,
Intervat
. ..Be)
(ms)
Responders to IVA In = 81 438 475' 36 .8
(4001o490) (42010540) (01.100)
Nneeesponde.sIn = 7) 414 453' 38 .6
(320,.51 ) (360 to 510) (0 to 100)
Pts with arrhythmia nsecerbotioa n = 2) 395 585 190
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were due to congestive heart failure and 2 were of noncar-
diac cause .
Of the four nonresponders who were discharged from the
hospital, follow-up was available for all four. One of these
patients (25%) died suddenly at 1 .3 years of follow-up
.
Discussion
In contrast to oral amiodarone, which requires 8 days to
4 weeks to be fully effective in patients with ventricular
arrhythmias (2-4), intravenously administered amiodarone
was shown in our study to be rapidly effective (0 to 84 h) in
58 .5% of patients with drug-refractory recurrent ventricular
tachycardia and ventricular fibrillation . It was effective in
combination with oral amiodarone in an additional 13% of
patients in 5 to 12 days . The reason for the delay in the onset
of effect in the second group of patients is not apparent from
our study . The rapid onset of the antiarrhythmic effect of
intravenous amiodarone is even more impressive when one
considers that in 33% of patients, the effect is virtually
immediate (0 to 2 h) .
Possible reasons for rapid onset of action, A rapid onset of
antiarrhythmic effect of intravenous amiodarone has not
been fully accepted because of conflicting reports of the
agent's effect on the ventricular effective refractory period.
Hariman et al . (13) and Wellens et al
. (14) reported a lack of
effect of intravenous amiodarone on the ventricular effective
refractory period after a dose of5 mg/kg, whereas Morady et
al . (15) reported a moderate effect after a dose of 10 mg/kg.
An effect on ventricular effective refractory period, how-
ever, may not be a requirement for an antiarrhythmic effect
of amiodarone for at least two reasons . First, amiodarone
may act predominantly on diseased myocardium, as sug-
gested by Hariman et al. (13), and may therefore not affect
the measured ventricular effective refractory period at elec-
trophysiologic study
. Second, amiodarone may exert anti-
arrhythmic effects (such as slowing of conduction) indepen-
dent of changes in refractoriness . Support for the latter
hypothesis was provided by Mason et al . (16), who demon-
strated that amiodarone primarily affects the sodium channel
in the inactivated state, an effect that would lead to slowing
of conduction without affecting refractoriness .
Because the primary mode of antiarrhythmic effect of
amiodarone is uncertain, the reason for the more rapid onset
of effect of intravenous amiodarone compared with that of
oral amiodarone is not clear
. One possible explanation is a
more rapid attainment of
a therapeutic serum level with
intravenous as compared with oral amiodarone
. Mostow et
al. (17) suggested that serum concentrations of amiodarone
associated with therapeutic responses in patients with recur-
rent ventricular tachycardia are >1.5 pg/ml
. Haffajee et al.
(I8) reported recurrence of ventricular tachycardia and
fibtilation when serum levels of amiodarone decreased to
<l .u ,g/ml
. Successful treatment with oral amiodarone has
JACC Vo1. 12, No. 4
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been reported (19) at serum concentrations as low as 0
.1 pg/
ml, however. Concentrations of 1 .0 to 1 .5 pg/ml are
achieved and maintained with oral amiodarone only after
several days of treatment, whereas they are achieved and
exceeded immediately after a 5 mg/kg infusion over 30 min
(20-22)
. The concentration is maintained at > 1 pg/mI when
such a bolus injection is followed by a continuous infusion of
10 to 20 mg/kg per day (23).
Predictors of positive response . In addition to finding that
intravenous amiodarone is rapidly effective, we observed
that the only pretreatment clinical characteristic that pre-
dicted a higher response rate to amiodarone was an ejection
fraction >25% . A higher efficacy of antiarrhythmic drugs in
patients with better left ventricular function has been re-
ported with other antarrhythmic agents (24-26).
Because all the patients in this study who had received
bretylium before treatment with intravenous amiodarone
had failed to respond to it, we could not assess whether
response to bretylium can predict response to intravenous
amiodarone . However, we found that in the 10 patients who
had been unsuccessfully treated with bretylium therapy, 8
ultimately responded to amiodarone, suggesting a difference
in the antiarrhythmic effect of these two drugs, both cur-
rently classified as class III .
QTc analysis. The efficacy oflong-term therapy with oral
amiodarone has been related to QT and QTc prolongation
(27) . We found, however, that responders and nonrespon-
ders to intravenous amiodarone did not differ in the magni-
tude or percent of QT or QTc prolongation . Whether this
difference between our findings and those reported for oral
amiodarone indicates a difference in the mechanism of action
of oral versus intravenous amiodarone remains to be
deter-
mined. We also found that the two patients who developed
a proarrhythmic response to intravenous amiodarone had
more marked QT and QTc prolongation when compared with
the group as a whole. This finding requires validation in a
larger group of patients.
Long-term follow-up. Long-term follow-up shows that
the incidence of recurrent ventricular arrhythmia (25%) . the
cumulative mortality due to arrhythmia recurrence or sud-
den death (23%) and the cumulative overall mortality (46%)
at 2 years for responders discharged from the hospital on
oral amiodarone are high . These findings suggest that in the
future, patients who require intravenous amiodarone for
drug-refractory ventricular tachycardia or ventricular fibril-
lation should be considered for other treatment modalities at
the time of hospital discharge . These can include automatic
implantable cardioyerter-defibrillator placement, coronary
artery bypass grafting and cardiac transplantation in appro-
priate patients . The clinical role of invasive electrophysiolo-
gic testing in the long-term management of patients followed
up on oral amiodarone therapy is still controversial (28-30) .
Limitations of she study
. The causes for initiation of
ventricular arrhythmias are frequently unclear
. It may,
JACC Vol . 12, No
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therefore, be impossible to distinguish spontaneous abate-
ment of the arrhythmia fromm a true therapeutic response . We
attempted to minimize this limitation by excluding patients
who had identifiable or correctab'e causes of their tachycar-
dia (i.e ., drug-induced, electrolyte abnormality, acute myo-
cardial inf.-ction), In addition, almost all our patients had
very frequetut or incessant episodes of
ventricular tachycar-
dia or ventricular fibrillation . Of note is the finding that the
percent of responders and the time course of response was
similar in patients with incessant ventricular tachycardia and
in the patient group as a whole .
A second limitation
of our study is the unc'rtainty
involved in attributing a successful response t3 the ant : .
arrhythmic effect of amiodarone because additional anti-
arrhythmic drugs were used in 15 of 33 responders . That the
positive response was primarily due to amiodarone is sug-
gested by the finding that all the drugs used concurrently
with amiodarone had been used without success before the
start of the infusion, and that the great majority of respond-
ers were discharged on amiodarone alone .
Fb:ally, no amiodarone serum levels were measured in
this study . Serum levels with infusion protocols
similar
to
ours have been reported by others (19-22) . However, the
comparison of serum levels in responders and nonrespond-
ers may help in the design of a more effective infusion
protoualin the future .
Cltnktd implications, We found a remarkable efficacy of
intravenous amiodarone in critically ill patients with recur-
rent ventricular arrhythmias. We found that those destined
to respond did so for the most part early in the treatment
course (i .e ., within 3 days). Those who do not respond early
might best be evaluated for alternative (including nonphar-
macologic) therapy. The only clinical characteristic associ-
ated with a response to intravenous amiodarone was better
left ventricular function
.
A negative response to bretylium
did not predict a similar response to intravenous amioda-
rone.
The long-term prognosis of responders who weredischarged
from the hospital on oral amiodarone therapy was
found to be poor ; therefore, alternative modes of therapy
should be considered once the patient's condition is stabi-
lized.
We are indebted to Badmen Kataurg, MD for helpful suggestions regarding
the manuscript
. We are greatly indebted to
Carol
Inaba in preparation of the
nmsuscdpt
.
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